Improving Treatment Outcomes in Pharmacotherapy of Generalized Social

Status Completed

Clinical Trial Summary

This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.

Clinical Trial Description

Generalized social anxiety disorder (GSAD) is one of the most common psychiatric disorders, and often causes significant distress and dysfunction in affected individuals. Although currently available treatments for GSAD are effective, most individuals have residual symptoms after initial psychosocial or psychopharmacologic intervention. Further treatment is necessary for such individuals, but sufficient research has not been done to guide clinicians on what the safest and most effective next step may be. This study will compare the effectiveness of either combining clonazepam or placebo with sertraline or completely switching to venlafaxine in treating GSAD in individuals who have not responded to treatment with sertraline. This study will also examine predictors of treatment response, including factors such as age at disease onset, duration of illness, comorbidities, and genes that influence serotonin and catecholamine metabolism.

Participants in this double-blind study will first partake in an initial 10-week phase in which they will be treated with sertraline. Participants who do not respond to sertraline treatment will proceed to phase two of the study, in which they will be randomly assigned to one of three treatment groups. One group will receive both sertraline and clonazepam, another group will receive both sertraline and placebo, and the third group will receive only venlafaxine. All treatments will continue for 12 weeks. Sertraline and venlafaxine are both FDA-approved for the treatment of GSAD. Clonazepam is widely used for the treatment of anxiety, but is not FDA-approved for the treatment of GSAD. All participants will attend weekly study visits at Weeks 1, 2, 4, 6, 8, and 10. Participants who continue into phase two will attend weekly study visits at Weeks 11-14, 16, 18, 20, and 22. Symptom remission rates and post-treatment social phobia severity will be assessed at Week 22. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00282828
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	March 2006
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02256566` - Cognitive Training for Mood and Anxiety Disorders	N/A
Completed	`NCT01570400` - Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT	N/A
Recruiting	`NCT01388231` - Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice	Phase 2/Phase 3
Completed	`NCT00684541` - Interpretation Modification Program for Social Phobia	N/A
Completed	`NCT00380731` - Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia	N/A
Completed	`NCT00434759` - Social Phobia Intervention Study of Mannheim	N/A
Completed	`NCT03647605` - Pilot Study: VR Mind and VR Mind+ Intervention	N/A
Not yet recruiting	`NCT03241277` - Nonsurgical Periodontal Treatment in Patients With Social Phobia	N/A
Completed	`NCT02648737` - Cognitive Behavioural Therapy for Anxiety Disorders in PD	N/A
Completed	`NCT02294409` - Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis	N/A
Terminated	`NCT01979263` - Attention Bias Modification Treatment for Anxious Youth	N/A
Completed	`NCT01463137` - Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder	N/A
Completed	`NCT00774150` - Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study	N/A
Completed	`NCT00264654` - Long-term Study Of Paroxetine in Women and Men	Phase 3
Completed	`NCT00326430` - Residential Cognitive and Interpersonal Therapy for Social Phobia	Phase 2/Phase 3
Completed	`NCT00000389` - Treatment for Anxiety in Children	Phase 3
Completed	`NCT00397722` - Treatment Of Patients With Social Anxiety Disorder	Phase 2
Completed	`NCT02678624` - Project Collabri for Treatment of Anxiety	N/A
Completed	`NCT00564967` - A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy	Phase 3
Completed	`NCT00403962` - A Combination Therapy In Patients With Social Anxiety Disorder	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms